MTX325
AssetAlso MTX115325
Inhibits USP30 to promote mitophagy.
- Stage
- Phase 1
- Modality
- Small molecule
- Target
- Mitochondrial biogenesis (PGC-1α)
- 3
- Indications
- 1
- Trial
- 1
- Developer
Indications
3Early stage Parkinson's disease
Phase 1, Recruiting, NCT07630545, clinicaltrials.gov, 7 Oct 2026
Mild to moderate Parkinson's disease
Phase 1, Recruiting, NCT07630545, clinicaltrials.gov, 7 Oct 2026
Parkinson's disease
Phase 1, missiontherapeutics.com, 10 Oct 2026
In the full profile
- Targets and what it contains4
- Owner and partners3
- Trials1
- Evidence for its targets3
- Competitors12
- Aging relevance3
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.